Evidence map›Paper›PMID 42333892›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Chemical Synthesis and Immunological Evaluation of Escherichia coli O29, Shigella dysenteriae Serotype 11, and Proteus vulgaris O12 O-Antigen Oligosaccharides.

Xinxin Li, Xiaotong Wang, Lei Deng, Xiang Ji, Yuanhong Tu, Can Liu, Zhen Wang, Liming Wang, Xinshan Ye, You Yang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xinxin LiNational Research Centre for Carbohydrate Synthesis, College of Chemistry and Materials, Jiangxi Normal University, Nanchang, China.
Xiaotong WangShanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, Engineering Research Center of Pharmaceutical Process Chemistry, Ministry of Education, East China University of Science and Technology, Shanghai, China.
Lei DengNational Research Centre for Carbohydrate Synthesis, College of Chemistry and Materials, Jiangxi Normal University, Nanchang, China.
Xiang JiShanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, Engineering Research Center of Pharmaceutical Process Chemistry, Ministry of Education, East China University of Science and Technology, Shanghai, China.
Yuanhong TuNational Research Centre for Carbohydrate Synthesis, College of Chemistry and Materials, Jiangxi Normal University, Nanchang, China.
Can LiuNational Research Centre for Carbohydrate Synthesis, College of Chemistry and Materials, Jiangxi Normal University, Nanchang, China.
Zhen WangNational Research Centre for Carbohydrate Synthesis, College of Chemistry and Materials, Jiangxi Normal University, Nanchang, China.
Liming WangNational Research Centre for Carbohydrate Synthesis, College of Chemistry and Materials, Jiangxi Normal University, Nanchang, China.
Xinshan YeState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, and Chemical Biology Center, Peking University, Beijing, China.ORCID 0000-0003-4113-506X
You YangShanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, Engineering Research Center of Pharmaceutical Process Chemistry, Ministry of Education, East China University of Science and Technology, Shanghai, China.ORCID 0000-0003-4438-2162
Qingju ZhangNational Research Centre for Carbohydrate Synthesis, College of Chemistry and Materials, Jiangxi Normal University, Nanchang, China.ORCID 0000-0002-6225-4183

Funding

National Natural Science Foundation of China 22167015National Natural Science Foundation of China 22377043National Natural Science Foundation of China 22407053National Natural Science Foundation of China 22577027Natural Science Foundation of ShanghaiScience and Technology Department of Jiangxi Province 20224ACB213006Science and Technology Department of Jiangxi Province 20244BDF60014Science and Technology Department of Jiangxi Province 2024SSY07051Science and Technology Department of Jiangxi Province 20252BAC220023Science and Technology Department of Jiangxi Province JXSQ2020101084Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism
6 · The paper itself

Abstract

Escherichia coli (E. coli), Shigella dysenteriae (S. dysenteriae), and Proteus vulgaris (P. vulgaris) are the leading bacterial causes of death and diseases in many countries. Vaccines are economical and effective tools against bacterial infection. Herein, we present the first total synthesis and immunological evaluation of the E. coli O29, S. dysenteriae serotype 11, and P. vulgaris O12 O-antigen decasaccharides, pentasaccharides, and related oligosaccharide fragments. We found that the hexasaccharide, including two repeating units of the core trisaccharide, was the optimal epitope, which was conjugated with the carrier protein CRM197 to furnish a semisynthetic glycoconjugate vaccine. The glycoconjugate vaccine induced a robust antigen-specific immune response, and the antibody sera could recognize the surface O-antigens of E. coli O29. This glycoconjugate vaccine, including a common trisaccharide fragment, existed in many bacterial O-antigens, which can be further used as a potential broad-spectrum vaccine against E. coli, S. dysenteriae, P. vulgaris, and Cronobacter malonaticus (C. malonaticus).

Indexed as

Escherichia coliO AntigensOligosaccharidesProteus vulgarisShigella dysenteriaeSerogroupO AntigensOligosaccharidesbroad‐spectrum vaccinecarbohydrate‐based vaccineE. coli O29oligosaccharide synthesisP. vulgaris O12

Identifiers

PMID42333892
PMCPMC13502573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.